Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
Clinical trial NCT03862807 · COMPLETED
Trial details
- NCT number
- NCT03862807
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-27
- Primary completion
- 2020-10-06
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.